AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06698562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Distraction with Virtual reality glassess
Description: the injection site was dried with a cotton pellet and placebo topical anaesthesia was applied with a pre-sterilised wooden ear stick in a circular motion followed by laser biostimulation. The Wiser diode laser (Doctor Smile, Vicenza, Italy), a diode laser device with a wavelength of 980 nm and equipped with a 600 μm diameter fibre, was used to deliver low-level laser therapy to the area of interest. The tip of the laser carrier system was placed at a distance of 1 cm from the target tissue without contact and applied with continuous circular movements as recommended by the manufacturer. A silicone piece was placed on the end of the carrier system to ensure that the distance to the tissue remained constant in each application. The focal spot area was determined as 0.087 cm2. The power of the laser used in our study was determined as 0.3 W and the application time was selected as 60 seconds. The patient and the physician wore protective goggles during the whole procedure to prevent possi
Study NCT06698562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Distraction with Virtual reality glassess + LLLT
Description: The injection area was dried with a cotton pellet before injection. A topical anaesthetic gel containing 20% benzocaine (Vision pat gel) was applied to the mucosal tissues to be injected using a pre-sterilised ear stick. After the application of the topical anaesthetic agent, the laser device was positioned in the same way, but without applying energy, and the sound of the laser device was pre-recorded and the study was blinded. In this way, a placebo effect was created and the patient was prevented from distinguishing between the laser and non-laser session. After this procedure, local anaesthesia was applied.
Study NCT06698562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tell Show Do Group + LLLT
Description: The injection site was dried with a cotton pellet and placebo topical anaesthesia was applied with a pre-sterilised wooden ear stick in a circular motion followed by laser biostimulation. The Wiser diode laser (Doctor Smile, Vicenza, Italy), a diode laser device with a wavelength of 980 nm and equipped with a 600 μm diameter fibre, was used to deliver low-level laser therapy to the area of interest. The tip of the laser carrier system was placed at a distance of 1 cm from the target tissue without contact and applied with continuous circular movements as recommended by the manufacturer. A silicone piece was placed on the end of the carrier system to ensure that the distance to the tissue remained constant in each application. The focal spot area was determined as 0.087 cm2. The power of the laser used in our study was determined as 0.3 W and the application time was selected as 60 seconds. During the whole procedure, the patient wore virtual glasses and the physician wore protective go
Study NCT06698562 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tell Show Do Group
Description: In this session, the injection area was dried with a cotton pellet before injection. A topical anaesthetic gel containing 20% benzocaine (Vision pat gel) was applied to the mucosal tissues to be injected using a pre-sterilised ear stick. After the application of the topical anaesthetic agent, the laser device was positioned in the same way, but without applying energy, and the sound of the laser device was pre-recorded and the study was blinded. In this way, a placebo effect was created and the patient was prevented from distinguishing between the laser and non-laser session. After this procedure, local anaesthesia was applied.
Study NCT06698562 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tell Show Do Group
Description: In this session, the injection area was dried with a cotton pellet before injection. A topical anaesthetic gel containing 20% benzocaine (Vision pat gel) was applied to the mucosal tissues to be injected using a pre-sterilised ear stick. After the application of the topical anaesthetic agent, the laser device was positioned in the same way, but without applying energy, and the sound of the laser device was pre-recorded and the study was blinded. In this way, a placebo effect was created and the patient was prevented from distinguishing between the laser and non-laser session. After this procedure, local anaesthesia was applied.
Study NCT04907721 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Glucagon Sensitivity test consisting of an amino acid tolerance test and a bolus infusion of glucagon
Description: The test consists of two experimental study days:~Day 1: intravenous bolus-injection of glucagon (0.2 mg at time 0 minutes) evaluating the effect of exogenous glucagon on amino acid disappearance. Blood samples will be obtained from time -10 to 120 minutes.~Day 2: 45-minute intravenous infusion of mixed amino acids (331 mg/min/kg body weight from time 0-45 minutes) to evaluate the effect of endogenous glucagon on amino acid metabolism. Blood samples will be obtained from time -10 to 180 minutes.~All participants will be subjected to a magnetic resonance imaging scan to assess whole-liver steatosis, and a bioelectrical impedance analysis to assess body composition.~Following study inclusion and the magnetic resonance imaging scan, participants will be stratified into groups based on hepatic steatosis. Individuals with \<5.6 % hepatic steatosis will be classified as controls and individuals with ≥5.6 % hepatic steatosis will be classified as MASLD.
Study NCT05463575 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketohexokinase inhibition
Description: participants will be asked to take 300 mg of the KHKi in tablet form daily for 6 weeks in either period 1 or 2.
Study NCT05463575 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: participants will be asked to take 300 mg of the placebo in tablet form daily for 6 weeks in either period 1 or period 2.
Study NCT05592964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Fasting
Description: Standard fasting
Study NCT05592964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Water
Description: In Group S, water was given 1 hour before the operation.
Study NCT05592964 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Intervention: Carbohydrate fluid
Description: In Group K, carbohydrate fluid was given 1 hour before the operation.
Study NCT06698380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: The subjects of the control group received the CPT based on their routine physical therapy neurological evaluation. The CPT was individualized based on the needs of the subjects. It included: normalization of muscle tone, strengthening of weak muscles, lengthening of tight muscles, training for transfers like supine to sit, sit to stand, balance training, and gait training. The upper extremity training for ADLs also were incorporated using mobilization, reaching, grasping and dexterity movements
Study NCT06698380 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mirror Therapy
Description: A mirror was positioned in front of the subjects to shield the involved upper extremity, reflecting the image of the uninvolved side. The involved upper extremity was placed in a relaxed posture beside the mirror, mirroring the same posture on the uninvolved side to enhance illusional movements. The MT for the experimental group included reaching, grasping, and dexterity movements of the unaffected upper limb, followed by imitation on the involved side. Subjects performed five activities: finger flexion and extension, finger opposition, counting with fingers, wrist flexion and extension, and forearm supination and pronation. Each activity was done 10 times, with mirror therapy lasting 15 minutes followed by 30 minutes of CPT treatment. Each session lasted 45 minutes, held three times per week over six weeks.
Study NCT06699251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chat
Description: Chat is a brief motivational interviewing intervention for partner clinic participants with an alcohol or cannabis use condition.
Study NCT06699251 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: An informational brochure will be give to partner clinic participants with an alcohol or cannabis use condition.
Study NCT06699472 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Vincristine (V), intravenous injection, 1.5 mg/m2 (maximum not exceeding 2mg), D1, odd cycle administration Doxorubicin (D), intravenous infusion, 75mg/m2, D1, odd cycle administration When the cumulative dose of doxorubicin is ≥ 375mg/m2, replace it with actinomycin D 1.25mg/m2 Cyclophosphamide (C), intravenous infusion, 1200mg/m2, D1, odd cycle administration Ifosfamide (I), intravenous infusion, 1800mg/m2, D1-5, even cycle administration Etoposide (E), intravenous infusion, 100mg/m2, D1-5, even cycle administration
Study NCT05031078 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gardasil
Description: Participants will receive 3 doses of 9-valent HPV vaccine (Gardasil 9) at D0, D60, and D180 The 9-valent HPV vaccine, or Gardasil-9, is a non-infectious recombinant vaccine prepared from the purified virus-like particles (VLPs) of the major capsid (L1) protein of HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58.~Gardasil-9 is supplied as a 0.5-mL single-dose vial or 0.5-mL single-dose prefilled Luer Lock syringe with tip cap.
Study NCT06699472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Vincristine (V), intravenous injection, 1.5 mg/m2 (maximum not exceeding 2mg), D1, odd cycle administration Doxorubicin (D), intravenous infusion, 75mg/m2, D1, odd cycle administration When the cumulative dose of doxorubicin is ≥ 375mg/m2, replace it with actinomycin D 1.25mg/m2 Cyclophosphamide (C), intravenous infusion, 1200mg/m2, D1, odd cycle administration Ifosfamide (I), intravenous infusion, 1800mg/m2, D1-5, even cycle administration Etoposide (E), intravenous infusion, 100mg/m2, D1-5, even cycle administration
Study NCT06699472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib Injection [Cosela]
Description: Trilaciclib, intravenous infusion, 240 mg/m2, administered following chemotherapy (2 hours after completion of vincristine administration and within 4 hours before administration of other chemotherapy drugs)
Study NCT06699862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training
Description: Throughout the 10-weeks intervention period, B2L-M HIIT sessions will be delivered during regular PE classes twice a week, by the schools' PE teachers. The HIIT sessions will be applied in the first 8-10 min of each PE class, including a brief warm-up involving a combination of aerobic and body weight muscle-strengthening exercises, and designed to be fun and engaging as well as vigorous in nature
Study NCT06699862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Interval Training with Competition
Description: Students will participate in a school competition to win points for their class for a 10-week period. In every HIIT session the heart rate will be tracked to measure the exercise intensity and also it will be used to win points for the competition. Every class will receive the same number of points as the sum of the minutes of exercise at a vigorous intensity (i.e., ≥85% max. heart rate) of each participant. This fact means that the physical fitness is irrelevant to the competition aspect, which will only consider the effort of the participants.
Study NCT06699394 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Teclistamab (Tec)
Description: Teclistamab is administered subcutaneously with the usual step-up dosing: 0.06 mg/kg at day 1, 0.3 mg/kg at day 4, 1.5 mg/kg at day 8, and then 1.5 mg/kg weekly.
Study NCT06699524 — intervention group
Intervention type: DRUG
Intervention: in vitro （chemotherapy）
Description: resuscitating PDTO from the organoid biobank, patients were categorized into drug-sensitive and drug-resistant groups based on the optimal cutoff value for PDTO drug testing. We then followed up to analyze the correlation between PDTO drug testing and RFS.
Study NCT06699524 — intervention group
Intervention type: DEVICE
Intervention: Adjuvant TACE（Adjuvant Transarterial Chemoembolization）
Description: Adjuvant TACE was performed 4 to 8 weeks postoperatively, with a chemotherapy regimen of 50 mg of doxorubicin and 50 mg of oxaliplatin.
Study NCT06699186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep
Description: A training programme was devised which involved the participants performing maximum squat repetitions with their own body weight as a workload, in order to induce delayed-onset muscle soreness in the quadriceps. Before the maximum squat repetition, all participants performed a warm-up programme including 5 minutes of walking. Participants were instructed to perform the maximum number of repetitions within the one minute allotted for each set of squats and, after a 10-second rest period, to continue the programme in the same cycle until exhaustion. In the initial 24-hour period following the intervention, participants were instructed to maintain their habitual sleep schedules. In consideration of the delayed-onset muscle soreness, which typically occurs between 24 to 48 hours following maximal squat intervention.The sleep group was instructed to engage in a minimum of six hours of sleep over the course of the 24-hour observation period.
Study NCT06699186 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-sleep
Description: A similar delayed-onset muscle soreness inducing protocol was applied to the sleep group.Participants in the non-sleep group were subjected to sleep restriction. The participants were permitted to sleep for a maximum of four hours in total over the course of the 24-hour period in non-sleep group.
Study NCT06699017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous anterior chest compression
Description: CACC is performed manually and the pressure applied will be maintained between 60 and 80 cmH2O.
Study NCT06698679 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: There is no intervention in this study. We will obtain blood from the recruited patients and assess the metabolites therein. This is an observational work.
Study NCT06699043 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nanocrystalline hydroxyapatite in putty form
Description: decortication will be performed by penetrating the cortical walls of the intrabony defect by using a round carbide bur of 0.2 mm diameter to reach the marrow space.~* Multiple perforations will performed not closer than 1mm from each other and deep enough to obtain bleeding from the spongiosa~* The intrabony defects in Group I will be received nanocrystalline hydroxyapatite in putty form as grafting material (NanoBone® SBX Putty).
Study NCT06699043 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Demineralized Bone Matrix allograft putty
Description: decortication will be performed by penetrating the cortical walls of the intrabony defect by using a round carbide bur of 0.2 mm diameter to reach the marrow space. • Multiple perforations will performed not closer than 1mm from each other and deep enough to obtain bleeding from the spongiosa • The intrabony defects in Group II will be received Demineralized Bone Matrix allograft putty as grafting material, in both groups will be use membrane to cover of the graft materials and finally will be sutured the flap.
Study NCT06700304 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: N1 Implant
Description: The N1 Implant is a type of implantable brain-computer interface.
Study NCT06700304 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: R1 Robot
Description: The R1 Robot is a robotic electrode thread inserter that implants the N1 Implant.
Study NCT06698991 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Plasma Exchange
Description: • Plasma exchange (1.5 times plasma exchange)~* Blood volume: 80ml/kg~* Plasma volume = Blood volume x (1 - Hematocrit/100)~* TPE volume = 1.5 x plasma volume~* Duration: 4 hours
Study NCT05673278 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bowel Ultrasound Scan
Description: Ultrasound scans will attempt to measure predefined criteria implemented in other research work using bowel ultrasound.~I - Bowel wall thickness II - Colour Doppler signal III - Loss of wall layer stratification IV - Loss of haustration V - Fatty wrapping VI - Motility in terminal ileum (TI) VII - Lymphadenopathy VIII - Abscess IX - Stricture~+ Image quality
Study NCT06226753 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Type of anaesthesia used
Description: Spinal anaesthesia will be used for closure of loop ileostomy
Study NCT06226753 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Type of anaesthesia used
Description: Spinal anaesthesia will be used for closure of loop ileostomy
Study NCT05654753 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: active FMT
Description: MaaT033®, a lyophilized full-ecosystem intestinal microbiota delayed release oral capsule containing native, donor-derived (pooled from 4-6 donors) microbiome product manufactured by MaaT Pharma® will be delivered orally. Patients will receive 20 Maat033 capsules, each containing approximatively 0.42 g of microbiome product at once at day 0, then 3 capsules/day from day 1 through day 20.
Study NCT05654753 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 20 capsules placebo, each containing placebo at once at day 0, then 3 capsules/day from day 1 through day 20.
Study NCT05031078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine injections
Description: 1-2% lidocaine injections.~1% lidocaine, an FDA approved local anesthetic, will be injected subcutaneously to numb the area of the lymph node being sampled; whereas 1-2% lidocaine will be injected into the tissue surrounding the area where the bone marrow will be removed. In adults the recommended dose is 7 mg/kg with a maximum of 500 mg.
Study NCT06698991 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma Exchange
Description: • Plasma exchange (1.5 times plasma exchange)~* Blood volume: 80ml/kg~* Plasma volume = Blood volume x (1 - Hematocrit/100)~* TPE volume = 1.5 x plasma volume~* Duration: 4 hours
Study NCT06698991 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study NCT06698991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study NCT06699069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control or Euthyroid group
Description: Fed on normal standard diet
Study NCT06699069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothyroid group
Description: Experimental hypothyroidism will be induced by administration of propylthiouracil for three weeks in the form of tablets diluted in water
Study NCT06699069 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypothyroid group received exercise
Description: Rats will be subjected to chronic swimming. The swimming protocol will consist of 8 weeks of low-intensity swimming exercise. The exercise groups will be adapted to a round water tank (70 cm × 70 cm) containing water at 28 ± 2°C for 3 days (10-45 min/day). The rats will then begin swimming, 45 min/day for the first two weeks at 10am and 60 min/day for the last six weeks at 10am
Study NCT05570617 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Coach Intervention
Description: The Transition Coach Intervention will include 8, 1-hour sessions over 6-months. The transition coach will independently meet one-on-one with each youth using an individualized, patient-centred approach beginning with an introductory session, followed by 5 sessions covering each topic in the Youth Transition Roadmap. These topics include: Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. The clinical psychologist will lead 2 sessions beginning with the Patient Health Questionnaire for Anxiety and Depression as a screening tool. The clinical psychologist will discuss psychological and social well-being in the context of their disease covering personally relevant issues/concerns.
Study NCT05570617 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care- Youth Transition Roadmap
Description: All participants will receive the Youth Transition Roadmap (standard of care) which discusses 5 domains of healthcare transition; Self-Advocacy, Medication Management, General Health, Lifestyle Issues and Future Planning related to education and vocation. This is an informational pamphlet and will not require any additional meetings with the patient beyond their normal healthcare interactions
Study NCT04719754 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Vaginal swab
Description: The other vaginal swab will be cultured on blood agar, chocolate agar, MacConkey agar and Sabourauds dextrose agar. The cultures will be incubated at 37ºC for 24-96 h or until the colonies appear.
Study NCT05721937 — intervention group
Intervention type: DRUG
Intervention: Abrocitinib
Description: taken by mouth
Study NCT06510140 — intervention group
Intervention type: BEHAVIORAL
Intervention: Detection of the Post-operative delirium (POD)
Description: Detection of the early Post-operative delirium (POD) to assess the performance of a new composite score with pre-operative frailty, and per-operative ElectroEncephaloGram (EEG).
Study NCT05370378 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hold Relax with Agonist Contraction
Description: 1. Participant will be in prone lying and heating pad will be applied on gluteal region for 10 to 15 minutes.~2. Passive sustained stretch to piriformis will be applied for 10 seconds.~3. The participant will be asked to actively contract the muscle for about 10 seconds (isometric contraction) and then relax.~4. Immediately after that participant is ask to again actively contract the muscle against therapist resistance for 6-10 seconds.~5. Ask the participant to relax while therapist will apply stretch the muscle to its new tissue tension barrier position and this position will be maintained for 30 seconds.~6. This maneuver is repeated for 3 to 4 repetitions, each starting from where the previous finished.